Full Press Release Details
NORTH CHICAGO, Ill.,April 2, 2020/PRNewswire/ --
| IRISH TAKEOVER PANEL |
| DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 |
| DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS |
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
| 1.KEYINFORMATION | |
| Name of person dealing(Note 1) | Robert Alpern |
| Company dealt in | AbbVie Inc. |
| Class of relevant security to which the dealings being disclosed relate (Note 2) | Common shares, par value $0.01 per share |
| Dateofdealing | 31 March 2020 |
1.KEYINFORMATION
Name of person dealing(Note 1)
Robert Alpern
Company dealt in
AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)
Common shares, par value $0.01 per share
Dateofdealing
31 March 2020
| 2.INTERESTS AND SHORT POSITIONS | ||||||
| (a) Interests and short positions (following dealing) in the class of relevant security dealt in(Note 3) | ||||||
| Long | Short | |||||
| Number | (%) | Number | (%) | |||
| (1) Relevant securities | 26,107 (0.002%) | |||||
| (2)Derivatives(otherthanoptions) | 7,023 stock equivalent units (0.000%) | |||||
| (3) Options and agreements to purchase/sell | N/A | |||||
| Total | 33,130 (0.002%) | |||||
2.INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in(Note 3)
Long
Short
Number
(%)
Number
(%)
(1) Relevant securities
26,107 (0.002%)
(2)Derivatives(otherthanoptions)
7,023 stock equivalent units (0.000%)
(3) Options and agreements to purchase/sell
N/A
Total
33,130 (0.002%)
| (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A | ||||||
| Class of relevant security: | Long | Short | ||||
| Number | (%) | Number | (%) | |||
| (1) Relevant securities | ||||||
| (2)Derivatives(otherthanoptions) | ||||||
| (3) Options and agreements to purchase/sell | ||||||
| Total | ||||||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:
Long
Short
Number
(%)
Number
(%)
(1) Relevant securities
(2)Derivatives(otherthanoptions)
(3) Options and agreements to purchase/sell
Total
| 3.DEALINGS(Note 4) | ||
| (a) Purchases and sales | ||
| Purchase/sale | Number of relevant securities | Price per unit(Note 5) |
3.DEALINGS(Note 4)
(a) Purchases and sales
Purchase/sale
Number of relevant securities
Price per unit(Note 5)
| (b) Derivatives transactions (other than options transactions) | |||
| Product name,e.g.CFD | Nature of transaction(Note 6) | Number of relevant securities(Note 7) | Price per unit(Note 5) |
| Stock equivalent unit | Director fee credit to stock equivalent unit account | 90 | $76.19 |
(b) Derivatives transactions (other than options transactions)
Product name,e.g.CFD
Nature of transaction(Note 6)
Number of relevant securities(Note 7)
Price per unit(Note 5)
Stock equivalent unit
Director fee credit to stock equivalent unit account
90
$76.19
| (c) Options transactions in respect of existing relevant securities | ||||||
| (i) Writing, selling, purchasing or varying | ||||||
| Productname,e.g.calloption | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates(Note 7) | Exerciseprice | Type,e.g.American,European etc. | Expirydate | Optionmoneypaid/receivedper unit(Note 5) |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Productname,e.g.calloption
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates(Note 7)
Exerciseprice
Type,e.g.American,European etc.
Expirydate
Optionmoneypaid/receivedper unit(Note 5)
| (ii) Exercising | ||
| Product name,e.g.calloption | Number of securities | Exercise price per unit(Note 5) |
(ii) Exercising
Product name,e.g.calloption
Number of securities
Exercise price per unit(Note 5)
| (d) Other dealings (including transactions in respect of new securities) (Note 4) | ||
| Natureoftransaction(Note 8) | Details | Priceperunit(if applicable)(Note 5) |
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Natureoftransaction(Note 8)
Details
Priceperunit(if applicable)(Note 5)
| 4. OTHER INFORMATION |
| Agreements, arrangements or understandings relating to options or derivatives |
| Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. |
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
| Is a Supplemental Form 8 attached?(Note 9) | YES/NO√ |
| Date of disclosure | 2 April 2020 |
| Contactname | Steven L. Scrogham |
| Telephonenumber | 847-938-6166 |
| Nameofofferee/offerorwithwhichactinginconcert | AbbVie Inc. |
| Specify category and nature of acting in concert status | Director of AbbVie Inc. |
Is a Supplemental Form 8 attached?(Note 9)
YES/NO√
Date of disclosure
2 April 2020
Contactname
Steven L. Scrogham
Telephonenumber
847-938-6166
Nameofofferee/offerorwithwhichactinginconcert
AbbVie Inc.
Specify category and nature of acting in concert status
Director of AbbVie Inc.